These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9155162)

  • 21. Ribozyme technology for cancer gene target identification and validation.
    Li QX; Tan P; Ke N; Wong-Staal F
    Adv Cancer Res; 2007; 96():103-43. PubMed ID: 17161678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1.
    Zhang ZZ; Zhang Q; Wu M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):165-70. PubMed ID: 16608066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes.
    Huesker M; Folmer Y; Schneider M; Fulda C; Blum HE; Hafkemeyer P
    Hepatology; 2002 Oct; 36(4 Pt 1):874-84. PubMed ID: 12297834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing.
    Jung HS; Lee SW
    Biochem Biophys Res Commun; 2006 Oct; 349(2):556-63. PubMed ID: 16945335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A ribozyme targeted to RNA polymerase gene of infectious bursal disease virus effectively cleaves and inhibits expression of the viral gene product.
    Akin A; Lin TL; Wu CC
    Acta Virol; 1999 Dec; 43(6):341-7. PubMed ID: 10825922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.
    Scanlon KJ; Jiao L; Funato T; Wang W; Tone T; Rossi JJ; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10591-5. PubMed ID: 1660142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribozyme-mediated reversal of the multidrug-resistant phenotype.
    Scanlon KJ; Ishida H; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11123-7. PubMed ID: 7972021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
    Funato T; Yoshida E; Jiao L; Tone T; Kashani-Sabet M; Scanlon KJ
    Adv Enzyme Regul; 1992; 32():195-209. PubMed ID: 1496917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic applications of group I intron-based trans-splicing ribozymes.
    Lee CH; Han SR; Lee SW
    Wiley Interdiscip Rev RNA; 2018 May; 9(3):e1466. PubMed ID: 29383855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
    Funato T
    Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic potential of ribozymes in haematological disorders.
    James HA
    Expert Opin Investig Drugs; 2000 May; 9(5):1009-20. PubMed ID: 11060723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribozymes and siRnas: from structure to preclinical applications.
    Sioud M
    Handb Exp Pharmacol; 2006; (173):223-42. PubMed ID: 16594618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of ribozymes for gene therapy.
    Sullivan SM
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic potential of ribozymes.
    James HA; Gibson I
    Blood; 1998 Jan; 91(2):371-82. PubMed ID: 9427689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral and anticancer ribozymes.
    Poeschla E; Wong-Staal F
    Curr Opin Oncol; 1994 Nov; 6(6):601-6. PubMed ID: 7827172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled, targeted, intracellular expression of ribozymes: progress and problems.
    Rossi JJ
    Trends Biotechnol; 1995 Aug; 13(8):301-6. PubMed ID: 7544984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleic acid enzymes as a novel generation of anti-gene agents.
    Sioud M
    Curr Mol Med; 2001 Nov; 1(5):575-88. PubMed ID: 11899232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.